Wilmington Savings Fund Society FSB Invests $566,000 in Cencora, Inc. (NYSE:COR)

Wilmington Savings Fund Society FSB acquired a new stake in shares of Cencora, Inc. (NYSE:COR) in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 2,515 shares of the company’s stock, valued at approximately $566,000.

Several other hedge funds have also made changes to their positions in COR. Arvest Bank Trust Division bought a new stake in shares of Cencora in the 3rd quarter worth approximately $218,000. World Investment Advisors LLC acquired a new position in Cencora in the third quarter valued at about $4,072,000. Virtu Financial LLC boosted its holdings in shares of Cencora by 112.2% in the 3rd quarter. Virtu Financial LLC now owns 10,227 shares of the company’s stock worth $2,302,000 after acquiring an additional 5,407 shares in the last quarter. Passumpsic Savings Bank increased its holdings in Cencora by 4.9% during the 3rd quarter. Passumpsic Savings Bank now owns 6,464 shares of the company’s stock valued at $1,455,000 after purchasing an additional 304 shares in the last quarter. Finally, Unigestion Holding SA lifted its position in Cencora by 31.9% during the 3rd quarter. Unigestion Holding SA now owns 149,989 shares of the company’s stock worth $33,749,000 after buying an additional 36,275 shares in the last quarter. Institutional investors own 97.52% of the company’s stock.

Insider Transactions at Cencora

In related news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction on Tuesday, November 19th. The shares were sold at an average price of $242.16, for a total value of $5,208,619.44. Following the completion of the transaction, the chairman now owns 306,752 shares of the company’s stock, valued at approximately $74,283,064.32. This trade represents a 6.55 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Insiders have sold a total of 93,018 shares of company stock valued at $22,478,942 over the last 90 days. 15.80% of the stock is owned by corporate insiders.

Cencora Stock Up 0.1 %

NYSE:COR opened at $232.24 on Monday. The stock has a 50-day simple moving average of $238.36 and a 200 day simple moving average of $234.14. Cencora, Inc. has a 52-week low of $195.83 and a 52-week high of $253.27. The company has a market cap of $44.89 billion, a PE ratio of 30.92, a PEG ratio of 1.54 and a beta of 0.45. The company has a debt-to-equity ratio of 4.84, a quick ratio of 0.53 and a current ratio of 0.88.

Cencora Increases Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Friday, November 29th. Stockholders of record on Friday, November 15th were issued a $0.55 dividend. The ex-dividend date of this dividend was Friday, November 15th. This is an increase from Cencora’s previous quarterly dividend of $0.51. This represents a $2.20 dividend on an annualized basis and a dividend yield of 0.95%. Cencora’s dividend payout ratio (DPR) is 29.29%.

Wall Street Analysts Forecast Growth

COR has been the topic of several research analyst reports. JPMorgan Chase & Co. increased their price target on shares of Cencora from $280.00 to $287.00 and gave the company an “overweight” rating in a research note on Wednesday, August 21st. Evercore ISI boosted their price target on shares of Cencora from $250.00 to $285.00 and gave the stock an “outperform” rating in a research note on Thursday, November 7th. Wells Fargo & Company reduced their price target on Cencora from $249.00 to $237.00 and set an “equal weight” rating on the stock in a research report on Friday. StockNews.com lowered Cencora from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 20th. Finally, Robert W. Baird boosted their price objective on shares of Cencora from $287.00 to $292.00 and gave the company an “outperform” rating in a report on Thursday, November 7th. Two investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $275.60.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.